SCHEMBL2255493

SCHEMBL2255493

CN(C)c1cccc(C(=O)Cc2ccnc(Cl)n2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.44
LMNA P02545 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
PDE5A O76074 1/20 0.41
KMT2A Q03164 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RAF1 P04049 1/20 0.40
ABL1 P00519 3/20 0.40
BCR P11274 3/20 0.40
ALDH1A1 P00352 2/20 0.38
CSF1R P07333 1/20 0.38
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
HSD17B10 Q99714 2/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
GFER P55789 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1642975 0.84 RORC (0.38) KDM4ESMN1; SMN2L3MBTL1ALDH1A1NPC1
SCHEMBL24760920 0.83 ERCC5 (0.47) KDM4ESMN1; SMN2KMT2AL3MBTL1ALDH1A1
SCHEMBL1127118 0.81 RAB9A (0.35) KDM4ELMNAKMT2AALDH1A1NPC1
SCHEMBL310067 0.80 RAB9A (0.44) KDM4ESMN1; SMN2KMT2AL3MBTL1ABL1
SCHEMBL29751869 0.80 CES2 (0.47) KDM4ELMNASMN1; SMN2KMT2AL3MBTL1
SCHEMBL2254963 0.80 CES2 (0.47) KDM4ELMNASMN1; SMN2KMT2AL3MBTL1
SCHEMBL24760727 0.80 RAB9A (0.53) KDM4ESMN1; SMN2KMT2AL3MBTL1ALDH1A1
SCHEMBL13905871 0.79 RAB9A (0.36) SMN1; SMN2KMT2AALDH1A1NPC1RAB9A
SCHEMBL13905926 0.78 ACHE (0.40) SMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL310975 0.78 GSK3B (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190280-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-08-04 US disclosed
US-20110190280-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-08-04 US disclosed
US-20110190280-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-08-04 US disclosed
EP-2197876-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS Glaxosmithkline LLC (US) 2010-06-23 EP disclosed
WO-2009032667-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190280-A1 Thiazole And Oxazole Kinase Inhibitors PDXK, MAP3K1, MAP4K2 KDM4E 1783/4885LMNA 3516/4885SMN1; SMN2 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.